Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer. Smyth EC, Sundar R. Lancet 2023;402:2168-2170.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Smyth EC, Sundar R. Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer. Lancet 2023;402:2168-2170.
PMID: 37871605